cilostazol has been researched along with Hyperplasia in 13 studies
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 9.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "to evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in iliac arteries of pigs submitted to balloon catheter angioplasty." | 7.81 | Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty. ( Longhi, JA; Pereira, AH, 2015) |
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 7.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| "To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis." | 7.75 | Cilostazol suppresses neointimal hyperplasia in canine vein grafts. ( Dardik, A; Kondo, Y; Kudo, FA; Miyazaki, K; Muto, A; Nishibe, M; Nishibe, T, 2009) |
| "A single topical administration of cilostazol may suppress neointimal hyperplasia by inhibiting cell proliferation and tenascin-C synthesis in free artery grafts, presenting the potential for clinical use in vascular surgery." | 7.72 | Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. ( Fujinaga, K; Imanaka-Yoshida, K; Onoda, K; Shimono, T; Shimpo, H; Takao, M; Yada, I; Yamamoto, K; Yoshida, T, 2004) |
| "Cilostazol-treated grafts had a thinner intima layer with less myocyte content compared with control grafts, amounting to an 82 percent decrease in total intima area compared with controls." | 5.40 | Topical cilostazol inhibits neointimal hyperplasia in a rat interposition vein graft model. ( Akelina, Y; Ascherman, JA; Malliaris, SD; Munabi, NCO, 2014) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 5.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "to evaluate whether systemic administration of cilostazol reduces neointimal hyperplasia in iliac arteries of pigs submitted to balloon catheter angioplasty." | 3.81 | Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty. ( Longhi, JA; Pereira, AH, 2015) |
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 3.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| " Recent studies have shown that cilostazol, a selective type 3 phosphodiesterase inhibitor, prevents neointimal hyperplasia and in-stent thrombosis in patients with diabetes after coronary angioplasty and stent implantation." | 3.75 | Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. ( Cho, WH; Choi, HS; Hur, SH; Jung, GS; Kim, BW; Kim, HS; Kim, HT; Kim, JG; Kim, MK; Lee, HJ; Lee, IK; Lee, KM; Lee, KU; Lim, JO; Park, KG, 2009) |
| "To evaluate the efficacy of oral administration of cilostazol, an antithrombotic agent, for the prevention of thrombotic occlusion and intimal hyperplasia after stenting." | 3.69 | Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. ( Kichikawa, K; Kimura, Y; Kubota, Y; Maeda, M; Makutani, S; Nishimine, K; Ohishi, H; Sakaguchi, S; Uchida, H; Yoshioka, T, 1995) |
| "Cilostazol-treated grafts had a thinner intima layer with less myocyte content compared with control grafts, amounting to an 82 percent decrease in total intima area compared with controls." | 1.40 | Topical cilostazol inhibits neointimal hyperplasia in a rat interposition vein graft model. ( Akelina, Y; Ascherman, JA; Malliaris, SD; Munabi, NCO, 2014) |
| "Cilostazol is known to inhibit intimal proliferation and accelerate endothelialization." | 1.34 | Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model. ( Katoh, O; Suzuki, T; Tsuchikane, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, Y | 1 |
| Kihara, Y | 1 |
| Okada, M | 1 |
| Inoue, Y | 1 |
| Tochizawa, S | 1 |
| Toga, K | 1 |
| Tachibana, K | 1 |
| Kimura, Y | 2 |
| Nishi, T | 1 |
| Hidaka, H | 1 |
| Nikuhinikov, PI | 1 |
| Bytsay, AN | 1 |
| Lysak, LI | 1 |
| Yatsenko, AI | 1 |
| Abramenko, AV | 1 |
| Chancharoenthana, W | 1 |
| Leelahavanichkul, A | 1 |
| Taratummarat, S | 1 |
| Wongphom, J | 1 |
| Tiranathanagul, K | 1 |
| Eiam-Ong, S | 1 |
| Malliaris, SD | 1 |
| Munabi, NCO | 1 |
| Akelina, Y | 1 |
| Ascherman, JA | 1 |
| Longhi, JA | 1 |
| Pereira, AH | 1 |
| Kudo, FA | 1 |
| Kondo, Y | 1 |
| Muto, A | 1 |
| Miyazaki, K | 1 |
| Dardik, A | 1 |
| Nishibe, M | 1 |
| Nishibe, T | 1 |
| Lee, KM | 1 |
| Lee, HJ | 1 |
| Kim, MK | 1 |
| Kim, HS | 2 |
| Jung, GS | 1 |
| Hur, SH | 1 |
| Kim, HT | 1 |
| Cho, WH | 1 |
| Kim, JG | 1 |
| Kim, BW | 1 |
| Lim, JO | 1 |
| Choi, HS | 1 |
| Lee, KU | 1 |
| Park, KG | 1 |
| Lee, IK | 1 |
| Takigawa, T | 1 |
| Tsurushima, H | 1 |
| Suzuki, K | 1 |
| Tsuruta, W | 1 |
| Nakamura, K | 1 |
| Matsumura, A | 1 |
| Fujinaga, K | 1 |
| Onoda, K | 1 |
| Yamamoto, K | 1 |
| Imanaka-Yoshida, K | 1 |
| Takao, M | 1 |
| Shimono, T | 1 |
| Shimpo, H | 1 |
| Yoshida, T | 1 |
| Yada, I | 1 |
| Tsuchikane, E | 1 |
| Suzuki, T | 2 |
| Katoh, O | 1 |
| Min, PK | 1 |
| Jung, JH | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 1 |
| Shim, WH | 1 |
| Lee, SW | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Hong, MK | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Seong, IW | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Kim, JH | 1 |
| Chun, KJ | 1 |
| Park, SJ | 1 |
| Kubota, Y | 1 |
| Kichikawa, K | 1 |
| Uchida, H | 1 |
| Maeda, M | 1 |
| Nishimine, K | 1 |
| Makutani, S | 1 |
| Sakaguchi, S | 1 |
| Yoshioka, T | 1 |
| Ohishi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for cilostazol and Hyperplasia
| Article | Year |
|---|---|
Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Vessels; Dr | 2007 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
11 other studies available for cilostazol and Hyperplasia
| Article | Year |
|---|---|
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Qui | 1998 |
[[Impact of plestazol preparation on hyperplasia of inter vascular layer in the patients, suffering obliterating atherosclerosis of the lower extremities arteries after reconstructive operations].]
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Biomarkers; Case-Control Studies; Cilostazol; | 2016 |
Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease.
Topics: Animals; Cilostazol; Disease Models, Animal; Hyperplasia; Kidney Failure, Chronic; Mice; Nephrectomy | 2017 |
Topical cilostazol inhibits neointimal hyperplasia in a rat interposition vein graft model.
Topics: Administration, Topical; Animals; Cilostazol; Graft Occlusion, Vascular; Hyperplasia; Neointima; Pla | 2014 |
Effect of cilostazol on neointimal hyperplasia in iliac arteries of pigs after transluminal angioplasty.
Topics: Angioplasty; Animals; Cilostazol; Hyperplasia; Iliac Artery; Neointima; Phosphodiesterase 3 Inhibito | 2015 |
Cilostazol suppresses neointimal hyperplasia in canine vein grafts.
Topics: Analysis of Variance; Animals; Apoptosis; Cilostazol; Dogs; Hyperplasia; In Situ Nick-End Labeling; | 2009 |
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Topics: Angioplasty, Balloon; Angiotensin II; Animals; Binding Sites; Blood Glucose; Carotid Arteries; Carot | 2009 |
Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Carotid Arteries; Carotid Artery Injuries; | 2012 |
Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts.
Topics: Administration, Topical; Animals; Arteries; Cell Division; Cells, Cultured; Cilostazol; Hyperplasia; | 2004 |
Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model.
Topics: Animals; Cilostazol; Coronary Vessels; Drug Delivery Systems; Equipment Design; Hyperplasia; Metals; | 2007 |
Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study.
Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Cilostazol; Dogs; Embolization, Therapeu | 1995 |